Celosia Therapeutics

🚀 Exciting News from Celosia Therapeutics Pty Ltd! 🚀 We are thrilled to announce the appointment of Dr Kathryn Sunn as our new CEO. With her extensive experience in the biotech industry and a proven track record of leadership, Dr. Sunn is poised to drive Celosia Therapeutics to new heights. Dr. Sunn's expertise and commitment to advancing healthcare align perfectly with our mission to deliver cutting-edge genetic therapeutic solutions. We are confident that under her leadership, Celosia Therapeutics will continue to thrive and make significant strides in the industry. Please join us in welcoming Dr. Kathryn Sunn to the Celosia Therapeutics family! 🌟 #Leadership #GeneTherapy #HealthcareInnovation #CelosiaTherapeutics #MacquarieUniversity #startup

Published today (in Neuron - https://lnkd.in/gdU7-KjV) is our research team’s latest paper on our most advanced MND/ALS genetic medicine – congratulations to Yazi Diana Ke, Annika van Hummel, Lars Ittner and the many other authors. This paper is the culmination of 15 years of dedicated research and offers hope to MND/ALS (and FTD) patients globally.    A story can be found in the Sydney Morning Herald (https://lnkd.in/gzCsQPJv) and on The Lighthouse (https://lnkd.in/gTx9pTfQ).   Celosia Therapeutics (as spin-off company from Macquarie University) is pleased to be in a position to help bring this discovery to patients and thanks the various funding organisations (National Health and Medical Research Council (NHMRC), MND Australia, FightMND and Macquarie University) for their long term committed support.    MND/ALS (https://lnkd.in/gpvwcztT) is a devastating disease with few therapeutic options. Whilst some years away we are very hopeful of bringing this novel genetic medicine to patients. This treatment targets a known cause of MND/ALS (and FTD) known as TDP-43. TDP-43 is an essential cellular protein, but in disease it becomes misplaced, mis-folded and toxic, eventually killing the motor neurone. This therapy aims to clear “vacuum” the toxic form of TDP-43, protecting motor neurones, preventing progression of the disease and hopefully reversing the symptoms.   Celosia Therapeutics is actively engaging with investors to help bring this (and other discoveries) to patients. Please follow our journey to defeat MND/ALS and other neurodegenerative diseases.   Yazi Diana Ke, Annika van Hummel, @carol au, Gabriella Chan, @wei siang lee, Julia van der Hoven, Magdalena Przybyla, Yuanyuan Deng, Miheer Sabale, @nicolle morey, Josefine Bertz, Astrid Feentje Feiten, Stefania Ippati @Claire H. Stevens, Shu Yang, Amadeus Gladbach, Nikolas Haass, Jillian Kril, Ian Blair, Fabien Delerue, Lars Ittner Melissa Ryan, James Linton, Kathryn Sunn, Roger Chung, Macquarie University Incubator, Dan Johnson, Dominic Rowe, merit cudkowicz, Glenda Halliday, Anna Grocholsky, Su-Ming Wong   #mnd #motorneuronedisease #neurodegenerative #als #amyotrophiclateralsclerosis #ftd #frontotemporaldementia #macquarieuniversity #geneticmedicine #MQIncubator #geneticmedicine

Looking forward to attending the RESI Conference in San Francisco on the 9th January. Great line up of speakers and the opportunity to network with leading investors from around the globe. https://lnkd.in/dxqsmMy #jpm2024 #resi #neurodegenerative #genetherapy #investor #als #mnd #alzheimersdisease #biotechnology

Celosia Therapeutics is presenting at #SeedShowcase! Join us in San Francisco this January 8–10, 2024 to attend our presentation. Register now to meet one-to-one: biotechshowcase.com or reach out directly. #als #mnd #genetherapy #neurodegenerative #biotechnology #investor